1
|
Guerreiro M, Aguilar-Gallardo C, Montoro J, Francés-Gómez C, Latorre V, Luna I, Planelles D, Carrasco MP, Gómez MD, González-Barberá EM, Aguado C, Sempere A, Solves P, Gómez-Seguí I, Balaguer-Rosello A, Louro A, Perla A, Larrea L, Sanz J, Arbona C, de la Rubia J, Geller R, Sanz MÁ, Sanz G, Luis Piñana J. Adoptive transfer of ex vivo expanded SARS-CoV-2-specific cytotoxic lymphocytes: A viable strategy for COVID-19 immunosuppressed patients? Transpl Infect Dis 2021; 23:e13602. [PMID: 33728702 PMCID: PMC8250091 DOI: 10.1111/tid.13602] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2021] [Accepted: 03/07/2021] [Indexed: 01/16/2023]
Abstract
Cellular and humoral response to acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infections is on focus of research. We evaluate herein the feasibility of expanding virus‐specific T cells (VST) against SARS‐CoV‐2 ex vivo through a standard protocol proven effective for other viruses. The experiment was performed in three different donors' scenarios: (a) SARS‐CoV‐2 asymptomatic infection/negative serology, (b) SARS‐CoV‐2 symptomatic infection/positive serology, and (c) no history of SARS‐CoV‐2 infection/negative serology. We were able to obtain an expanded VST product from donors 1 and 2 (1.6x and 1.8x increase of baseline VST count, respectively) consisting in CD3 + cells (80.3% and 62.7%, respectively) with CD4 + dominance (60% in both donors). Higher numbers of VST were obtained from the donor 2 as compared to donor 1. T‐cell clonality test showed oligoclonal reproducible peaks on a polyclonal background for both donors. In contrast, VST could be neither expanded nor primed in a donor without evidence of prior infection. This proof‐of‐concept study supports the feasibility of expanding ex vivo SARS‐CoV‐2‐specific VST from blood of convalescent donors. The results raise the question of whether the selection of seropositive donors may be a strategy to obtain cell lines enriched in their SARS‐CoV‐2‐specificity for future adoptive transfer to immunosuppressed patients.
Collapse
Affiliation(s)
- Manuel Guerreiro
- Hematology Department, Hospital Universitari i Politècnic la Fe, Valencia, Spain.,Instituto de Investigación Sanitaria La Fe (IIS-La Fe), Valencia, Spain
| | - Cristóbal Aguilar-Gallardo
- Hematology Department, Hospital Universitari i Politècnic la Fe, Valencia, Spain.,Instituto de Investigación Sanitaria La Fe (IIS-La Fe), Valencia, Spain
| | - Juan Montoro
- Hematology Department, Hospital Universitari i Politècnic la Fe, Valencia, Spain.,Instituto de Investigación Sanitaria La Fe (IIS-La Fe), Valencia, Spain
| | - Clara Francés-Gómez
- Institute for Integrative Systems Biology (I2SysBio), Universidad de Valencia-CSIC, Valencia, Spain
| | - Víctor Latorre
- Institute for Integrative Systems Biology (I2SysBio), Universidad de Valencia-CSIC, Valencia, Spain
| | - Irene Luna
- Hematology Department, Hospital Universitari i Politècnic la Fe, Valencia, Spain
| | - Dolores Planelles
- Centro de Transfusión de la Comunidad Valenciana, Valencia, Spain.,Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO), Valencia, Spain
| | - María Paz Carrasco
- Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO), Valencia, Spain
| | - María Dolores Gómez
- Microbiology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain
| | | | - Cristina Aguado
- Service of Clinical Pathology, Hospital Universitari I Politècnic la Fe, Valencia, Spain
| | - Amparo Sempere
- Hematology Department, Hospital Universitari i Politècnic la Fe, Valencia, Spain.,CIBERONC, Instituto Carlos III, Madrid, Spain
| | - Pilar Solves
- Hematology Department, Hospital Universitari i Politècnic la Fe, Valencia, Spain
| | - Inés Gómez-Seguí
- Hematology Department, Hospital Universitari i Politècnic la Fe, Valencia, Spain
| | - Aitana Balaguer-Rosello
- Hematology Department, Hospital Universitari i Politècnic la Fe, Valencia, Spain.,Instituto de Investigación Sanitaria La Fe (IIS-La Fe), Valencia, Spain
| | - Alberto Louro
- Instituto de Investigación Sanitaria La Fe (IIS-La Fe), Valencia, Spain
| | - Aurora Perla
- Hematology Department, Hospital Universitari i Politècnic la Fe, Valencia, Spain
| | - Luis Larrea
- Centro de Transfusión de la Comunidad Valenciana, Valencia, Spain.,Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO), Valencia, Spain
| | - Jaime Sanz
- Hematology Department, Hospital Universitari i Politècnic la Fe, Valencia, Spain.,CIBERONC, Instituto Carlos III, Madrid, Spain
| | - Cristina Arbona
- Centro de Transfusión de la Comunidad Valenciana, Valencia, Spain.,Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO), Valencia, Spain
| | - Javier de la Rubia
- Hematology Department, Hospital Universitari i Politècnic la Fe, Valencia, Spain
| | - Ron Geller
- Institute for Integrative Systems Biology (I2SysBio), Universidad de Valencia-CSIC, Valencia, Spain
| | - Miguel Ángel Sanz
- Instituto de Investigación Sanitaria La Fe (IIS-La Fe), Valencia, Spain
| | - Guillermo Sanz
- Hematology Department, Hospital Universitari i Politècnic la Fe, Valencia, Spain.,CIBERONC, Instituto Carlos III, Madrid, Spain
| | - José Luis Piñana
- Hematology Department, Hospital Universitari i Politècnic la Fe, Valencia, Spain.,CIBERONC, Instituto Carlos III, Madrid, Spain.,Hematology Department, Hospital Clinico Universitario de Valencia, INCLIVA, Valencia, Spain
| |
Collapse
|
2
|
Guerreiro M, Planelles D, Aguilar-Gallardo C, Lorenzo JI, Montoro J, Sanz J, Balaguer A, Gómez I, Solves P, Pérez A, Blanquer M, Espigado I, Solano C, Piñana JL. Allogeneic hematopoietic stem cell transplant recipients in Spain: Human leukocyte antigen characteristics and diversity by high-resolution analysis. HLA 2021; 97:198-213. [PMID: 33369244 DOI: 10.1111/tan.14179] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2020] [Revised: 11/20/2020] [Accepted: 12/24/2020] [Indexed: 11/26/2022]
Abstract
There are many studies on the polymorphism of the HLA system in healthy donor populations, such as registries of unrelated bone marrow donors. Investigations on the characterization of the HLA complex in hematopoietic stem cell transplant (HSCT) patients, however, are scarce, at least in the Spanish population. This study presents a large-scale analysis of allelic diversity and HLA distribution at a high-resolution level in 2886 patients undergoing HSCT in Spanish centres of the "Grupo Español de Trasplante Hematopoyético y Terapia Celular" during a period of 11 years. Allelic diversity analysis identified 67 HLA-A, 133 HLA-B, 60 HLA-C, 63 HLA-DRB1, 24 HLA-DQB1 and 27 HLA-DPB1 different alleles. Rare alleles were detected among which 33 alleles had not been reported in the European catalog of common and well-documented HLA alleles. Regarding the distribution of five genes-haplotypes, it was observed that the five most frequent extended haplotypes found in our population were between the most common in other Spanish populations, both in patients and in healthy subjects. However, some particular haplotypes were also detected. Bilocus associations HLA-C ~ B and -DRB1 ~ DQB1 were analyzed in order to predict the probability of finding 10/10 matched donors in registries. We found HLA-B alleles showing a great diversity of combinations with HLA-C alleles and unusual associations involving a negative predicting factor. In the field of adoptive therapies, our work supports the necessity to expand further research of TCR-engineered cells, adoptive transfer of virus-specific T-cells and vaccines to target HLA alleles other than A*02:01. HLA alleles such as A*01:01, A*03:01, A*24:02, B*44:03, B*07:02 or B*51:01, might be considered new targets due to its high frequency in our population.
Collapse
Affiliation(s)
- Manuel Guerreiro
- Haematology Department, Hospital Universitari i Politècnic la Fe, Valencia, Spain
| | - Dolores Planelles
- Department of Histocompatibility, Centro de Transfusión de la Comunidad Valenciana, Valencia, Spain
| | | | - José Ignacio Lorenzo
- Haematology Department, Hospital Universitari i Politècnic la Fe, Valencia, Spain
| | - Juan Montoro
- Haematology Department, Hospital Universitari i Politècnic la Fe, Valencia, Spain
| | - Jaime Sanz
- Haematology Department, Hospital Universitari i Politècnic la Fe, Valencia, Spain
| | - Aitana Balaguer
- Haematology Department, Hospital Universitari i Politècnic la Fe, Valencia, Spain
| | - Inés Gómez
- Haematology Department, Hospital Universitari i Politècnic la Fe, Valencia, Spain
| | - Pilar Solves
- Haematology Department, Hospital Universitari i Politècnic la Fe, Valencia, Spain
| | - Ariadna Pérez
- Haematology Department, Hospital Clínico Universitario. Fundación INCLIVA, Valencia, Spain
| | - Miguel Blanquer
- Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH), Madrid, Spain.,Cell Therapy Unit, IMIB-University Hospital Virgen de la Arrixaca, Faculty of Medicine, University of Murcia, Murcia, Spain
| | - Ildefonso Espigado
- Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH), Madrid, Spain.,Haematology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain
| | - Carlos Solano
- Haematology Department, Hospital Clínico Universitario. Fundación INCLIVA, Valencia, Spain.,Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH), Madrid, Spain
| | - José Luis Piñana
- Haematology Department, Hospital Universitari i Politècnic la Fe, Valencia, Spain.,Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH), Madrid, Spain.,Hematology Division, CIBERONC, Instituto Carlos III, Madrid, Spain
| | | |
Collapse
|
3
|
Amado Labrador H, Jantus-Lewintre E, Calabuig Fariñas S, Aguilar-Gallardo C, Murga J, Munera-Maravilla E, Durendez-Saez E, Mosqueda M, Escorihuela E, Zhang F, Masiá E, Dong N, Guijarro R, Camps C. High-throughput screening of new drugs targeting lung CSCs. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy303.059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
4
|
Pomares AH, Aguilar-Gallardo C, Amado H, Escorihuela E, Blasco A, Calabuig-Fariñas S, Murga-Clausell J, Jantus-Lewintre E, Camps C. Abstract 3056: Lung tumor spheres as in vitro platform for testing new therapeutic strategies against cancer stem cells. Cancer Res 2018. [DOI: 10.1158/1538-7445.am2018-3056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Treatment resistance is related to cancer stem cells (CSCs), a highly tumorigenic subpopulation of cells capable of growing and forming tumor spheres under non-adherent conditions. This study aimed to isolate and characterise CSCs from resected non-small cell lung cancer (NSCLC) patients' tumor-tissue and cell lines like tumor spheres and to use them as an in vitro platform for drug screening.
Methods: The study was performed on tumour cells from 8 resected NSCLC patients and 12 NSCLC cell lines grown in monolayer and as spheres. The expression of 60 genes, including CSC-markers, pluripotency inducers, cell cycle regulators and components of the Notch, Wnt and Hedgehog pathways was analysed by RTqPCR. Protein levels of relevant markers were assessed by WB and IF. Based on CSCs' characterization, two new-synthetized compounds, called compound A and compound B, were tested in the 12 cell lines and on tumour cells from 4 resected NSCLC patients, in 8 different concentrations. Cell viability was measured after 48 hours using MTS assay normalized to the respective mock-treated control cells and presented as a percentage of the control. Statistical analyses were considered significant at p<0.05.
Results: Patients´ median age was 65 years [56-76], 73.3% were male and 45% were adenocarcinomas. Lung tumor spheres had a significantly higher expression of CSC-related genes CD44, ALDH1A1, CD90, CDKN1A, JUNB, NANOG, KLF4 and MDM2 than their paired-adherent cells. Invasion promoters SNAI1, ITGA6, and MMP9 were overexpressed in tumor spheres. Notch pathway ligands, JAG1 and DLL4, and receptors, NOTCH1 and NOTCH3, showed increased expression in spheroids than in differentiated cells. In Wnt, higher expression levels of CTNNB1 and GSK3B were found in spheres; when comparing the expression for both conditions. WB and IF revealed that EpCAM, CD44, ALDH1A1, Sox2 and β-catenin were overexpressed in spheroids whereas E-cadherin was overexpressed in the adherent cells. Drug screening showed that classical anticancer drugs had mild cytotoxic effects on both conditions. Stemness pathways inhibitors IWP2, XAV939, Salinomycin and Vismodegib had stronger cytotoxic effects on spheroids than on the cells grown in monolayers. Cytotoxic effect was stronger in the tumor spheres of the lines and patients treated with compounds A and B. Currently, these compounds are being tested in vivo, in tumors induced in xenografts with cells of patients tested in vitro, to determine the mechanism of action and cytotoxic effect on cancer stem cells in the future.
Conclusions: Our data suggest that lung tumor spheres provide a useful short-term culture platform for the simple and cost-effective characterization of CSCs. We found molecules that could be used as novel therapeutic approach in NSCLC. Supported by grants RD12/0036/0025 from RTICC-FEDER, and PI12-02838 and PI15-00753 from ISCIII.
Citation Format: Alejandro Herreros Pomares, Cristóbal Aguilar-Gallardo, Hector Amado, Eva Escorihuela, Ana Blasco, Silvia Calabuig-Fariñas, Juan Murga-Clausell, Eloísa Jantus-Lewintre, Carlos Camps. Lung tumor spheres as in vitro platform for testing new therapeutic strategies against cancer stem cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 3056.
Collapse
Affiliation(s)
| | | | - Hector Amado
- 2Fundación para la Investigación, Hospital General de Valencia, Valencia, Spain
| | - Eva Escorihuela
- 1Fundación para la Investigación, Hospital General de Valencia -CIBERONC, Valencia, Spain
| | - Ana Blasco
- 3Hospital General Universitario de Valencia-CIBERONC, Valencia, Spain
| | - Silvia Calabuig-Fariñas
- 4Fundación para la Investigación, Hospital General de Valencia -CIBERONC; Departament de Patologia, Universitat de València, Valencia, Spain
| | - Juan Murga-Clausell
- 5Dept de Química Inorgànica i Orgànica, Universitat Jaume I, Castellón, Spain
| | - Eloísa Jantus-Lewintre
- 6Fundación para la Investigación, Hospital General de Valencia -CIBERONC; Dept Biotecnologia, Universitat Politècnica de València, Valencia, Spain
| | - Carlos Camps
- 7Fundación para la Investigación, Hospital General de Valencia -CIBERONC; Dept Medicina, Universitat de València; Servicio de Oncología Médica, Hospital General Universitario de Valencia, Valencia, Spain
| |
Collapse
|
5
|
Herreros-Pomares A, Aguilar-Gallardo C, Calabuig-Fariñas S, Sirera R, Jantus-Lewintre E, Camps C. EpCAM duality becomes this molecule in a new Dr. Jekyll and Mr. Hyde tale. Crit Rev Oncol Hematol 2018; 126:52-63. [DOI: 10.1016/j.critrevonc.2018.03.006] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2018] [Revised: 03/16/2018] [Accepted: 03/17/2018] [Indexed: 02/08/2023] Open
|
6
|
Amado Labrador H, Aguilar-Gallardo C, Herreros-Pomares A, Munera-Maravilla E, Calabuig-Fariñas S, Escorihuela E, Murga J, Jantus-Lewintre E, Camps C. New generation of cancer stem cells inhibitors in non-small cell lung cancer. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.15_suppl.e20545] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | | | - Ester Munera-Maravilla
- Centro Investigaciones Energéticas, Medioambientales y Tecnológicas
- CIEMAT · Oncología Molecular, Madrid, Spain
| | - Silvia Calabuig-Fariñas
- Laboratorio de Oncología Molecular, FIHGUV; CIBERONC; Departament de Patologia, Universitat de València, Valencia, Spain
| | - Eva Escorihuela
- Laboratorio de Oncología Molecular, FIHGUV; CIBERONC, Valencia, Spain
| | - Juan Murga
- Dep. de Química Inorgánica y Orgánica, Univ. Jaume I, Castellón, Castellón, Spain
| | - Eloisa Jantus-Lewintre
- Laboratorio de Oncología Molecular, FIHGUV; CIBERONC; Departamento de Biotecnología, Universitat Politècnica de València, Valencia, Spain
| | - Carlos Camps
- Laboratorio de Oncología Molecular, FIHGUV; CIBERONC; Servicio de Oncología Médica, HGUV; Departament de Medicina, Universitat de València, Valencia, Spain
| |
Collapse
|
7
|
Herreros-Pomares A, de Maya JD, Amado H, Aguilar-Gallardo C, Escorihuela E, Blasco A, Calabuig-Fariñas S, Martorell M, Guijarro R, Jantus-Lewintre E, Farras R, Camps C. A gene expression signature to characterize human lung adenocarcinoma cancer stem cells. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.15_suppl.e20547] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - Juan Diego de Maya
- Laboratorio de Señalización Oncogénica, Centro de Investigación Príncipe Felipe (CIPF), Valencia, Spain
| | - Héctor Amado
- Laboratorio de Oncología Molecular, FIHGUV, Valencia, Spain
| | | | - Eva Escorihuela
- Laboratorio de Oncología Molecular, FIHGUV; CIBERONC, Valencia, Spain
| | - Ana Blasco
- Servicio de Oncología Médica, Hospital General Universitario de Valencia (HGUV), Valencia, Spain
| | - Silvia Calabuig-Fariñas
- Laboratorio de Oncología Molecular, FIHGUV; CIBERONC; Departament de Patologia, Universitat de València, Valencia, Spain
| | - Miguel Martorell
- Servicio de Anatomía Patológica, HGUV; Departament de Patologia, Universitat de València, Valencia, Spain
| | - Ricardo Guijarro
- Servicio de Cirugía Torácica, HGUV; Departament de Cirurgia, Universitat de València, Valencia, Spain
| | - Eloisa Jantus-Lewintre
- Laboratorio de Oncología Molecular, FIHGUV; CIBERONC; Departamento de Biotecnología, Universitat Politècnica de València, Valencia, Spain
| | - Rosa Farras
- Laboratorio de Señalización Oncogénica, CIPF, Valencia, Spain
| | - Carlos Camps
- Laboratorio de Oncología Molecular, FIHGUV; CIBERONC; Servicio de Oncología Médica, HGUV; Departament de Medicina, Universitat de València, Valencia, Spain
| |
Collapse
|
8
|
Duréndez-Sáez E, Azkárate A, Meri M, Calabuig-Fariñas S, Aguilar-Gallardo C, Blasco A, Jantus-Lewintre E, Camps C. New insights in non-small-cell lung cancer: circulating tumor cells and cell-free DNA. J Thorac Dis 2017; 9:S1332-S1345. [PMID: 29184672 DOI: 10.21037/jtd.2017.06.112] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
Lung cancer is the second most frequent tumor and the leading cause of death by cancer in both men and women. Increasing knowledge about the cancer genome and tumor environment has led to a new setting in which morphological and molecular characterization is needed to treat patients in the most personalized way in order to achieve better outcomes. Since tumor products can be detected in body fluids, the liquid biopsy, particularly, peripheral blood, has emerged as a new source for lung cancer biomarker's analysis. A variety of tumor components can be used for this purpose. Among them, circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) should be especially considered. Different detection methods for both CTCs and ctDNA have been and are being developed to improve the sensitivity and specificity of these tests. This would lead to better characterization and would solve some clinical doubts at different disease evolution times, e.g., intratumoral or temporal heterogeneity, difficulty in the obtaining a tumor sample, etc., and would also avoid the side effects of very expensive and complicated tumor obtaining interventions. CTCs and ctDNA are useful in different lung cancer settings. Their value has been shown for the early diagnosis, prognosis, prediction of treatment efficacy, monitoring responses and early detection of lung cancer relapse. CTCs have still not been validated for use in clinical settings in non-small-cell lung cancer (NSCLC), while ctDNA has been approved by the Food and Drug Administration (FDA) and European Medical Association (EMA), and the main clinical guidelines used for detect different epidermal growth factor receptor (EGFR) mutations and the monitoring and treatment choice of mutated patients with tyrosine kinase inhibitors (TKIs). This review, describes how ctDNA seem to be winning the race against CTCs from the laboratory bench to clinical practice due to easier obtaining methods, manipulation and its implementation into clinical practice.
Collapse
Affiliation(s)
- Elena Duréndez-Sáez
- Molecular Oncology Laboratory, Fundación Hospital General Universitario de Valencia, Valencia, Spain
| | - Aitor Azkárate
- Department of Oncology, University Hospital Son Espases, Palma de Mallorca, Spain
| | - Marina Meri
- Department of Medical Oncology, Hospital General Universitario de Valencia, Valencia, Spain
| | - Silvia Calabuig-Fariñas
- Molecular Oncology Laboratory, Fundación Hospital General Universitario de Valencia, Valencia, Spain.,Department of Pathology, Universitat de València, Valencia, Spain.,CIBERONC, Valencia, Spain
| | | | - Ana Blasco
- Department of Medical Oncology, Hospital General Universitario de Valencia, Valencia, Spain.,CIBERONC, Valencia, Spain
| | - Eloisa Jantus-Lewintre
- Molecular Oncology Laboratory, Fundación Hospital General Universitario de Valencia, Valencia, Spain.,CIBERONC, Valencia, Spain.,Department of Biotechnology, Universitat Politècnica de València, Valencia, Spain
| | - Carlos Camps
- Molecular Oncology Laboratory, Fundación Hospital General Universitario de Valencia, Valencia, Spain.,Department of Medical Oncology, Hospital General Universitario de Valencia, Valencia, Spain.,CIBERONC, Valencia, Spain.,Department of Medicine, Universitat de València, Valencia, Spain
| |
Collapse
|
9
|
Abstract
The stem cell field owes a great deal to the previous work conducted by embryologists and researchers devoted to reproductive medicine. The time is coming when this emerging field will pay off in the reproductive sciences by offering new avenues of understanding gametogenesis and early embryonic development. Human embryonic stem cells are pluripotent cells that proliferate in vitro while maintaining an undifferentiated state, and they are capable of differentiating into most cell types under appropriate conditions. Embryo-friendly approaches have been developed as new methods of obtaining human embryonic stem cells without destroying the embryo. Somatic stem cells have been identified and isolated from numerous adult organs and tissues to create a multipotent and autologous source of cells with established medical indications. Cell reprogramming is now a scientific fact, and induced pluripotent cells, a new pluripotent cell type, have been generated by the overexpression of specific genes from a myriad of differentiated adult cell types. Cancer is now considered a stem cell disease. Cancer stem cells share numerous features with normal stem cells including hallmarks properties such as self-renewal and undifferentiation. Therefore, the actual focus of ovarian cancer research on the cancer stem cell model should generate efficient and personalized treatment designs to improve treatment efficiency.
Collapse
|
10
|
Carcel-Trullols J, Aguilar-Gallardo C, Garcia-Alcalde F, Pardo-Cea MA, Dopazo J, Conesa A, Simón C. Transdifferentiation of MALME-3M and MCF-7 Cells toward Adipocyte-like Cells is Dependent on Clathrin-mediated Endocytosis. Springerplus 2012; 1:44. [PMID: 23961369 PMCID: PMC3725915 DOI: 10.1186/2193-1801-1-44] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/14/2012] [Accepted: 10/03/2012] [Indexed: 01/19/2023]
Abstract
Abstract Enforced cell transdifferentiation of human cancer cells is a promising alternative to conventional chemotherapy. We previously identified albumin-associated lipid- and, more specifically, saturated fatty acid-induced transdifferentiation programs in human cancer cells (HCCLs). In this study, we further characterized the adipocyte-like cells, resulting from the transdifferentiation of human cancer cell lines MCF-7 and MALME-3M, and proposed a common mechanistic approach for these transdifferentiating programs. We showed the loss of pigmentation in MALME-3M cells treated with albumin-associated lipids, based on electron microscopic analysis, and the overexpression of perilipin 2 (PLIN2) by western blotting in MALME-3M and MCF-7 cells treated with unsaturated fatty acids. Comparing the gene expression profiles of naive melanoma MALME-3M cells and albumin-associated lipid-treated cells, based on RNA sequencing, we confirmed the transcriptional upregulation of some key adipogenic gene markers and also an alternative splicing of the adipogenic master regulator PPARG, that is probably related to the reported up regulated expression of the protein. Most importantly, these results also showed the upregulation of genes responsible for Clathrin (CLTC) and other adaptor-related proteins. An increase in CLTC expression in the transdifferentiated cells was confirmed by western blotting. Inactivation of CLTC by chlorpromazine (CHP), an inhibitor of CTLC mediated endocytosis (CME), and gene silencing by siRNAs, partially reversed the accumulation of neutral lipids observed in the transdifferentiated cells. These findings give a deeper insight into the phenotypic changes observed in HCCL to adipocyte-like transdifferentiation and point towards CME as a key pathway in distinct transdifferentiation programs. Disclosures Simon C and Aguilar-Gallardo C are co-inventors of the International Patent Application No. PCT/EP2011/004941 entitled “Methods for tumor treatment and adipogenesis differentiation”. Electronic supplementary material The online version of this article (doi:10.1186/2193-1801-1-44) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Jaime Carcel-Trullols
- Bioinformatics and Genomics Department, Prince Felipe Research Centre (CIPF), Avda. Autopista del Saler, 16-3 46012 Valencia, Spain
| | | | | | | | | | | | | |
Collapse
|
11
|
|